Fig. 3
From: Primary resistance to first-generation EGFR-TKIs induced by MDM2 amplification in NSCLC
MDM2 amplification predicts a poor prognosis in NSCLC patients. a The genomic signatures of NSCLC patients derived from cBioportal for Cancer Genomics: 20% NSCLC patients were detected harboring EGFR alterations and 6% of them were detected harboring MDM2 alterations; B1-B2. The survival analyses of NSCLC patients grouped by genomic signatures of EGFR and MDM2 (DFS: disease free survival; OS: overall survival): NSCLC patients harboring the concurrent alterations of EGFR and MDM2 have a poor OS (P < 0.001); C1-C2. The survival analyses of NSCLC patients grouped by MDM2 expression: NSCLC patients with higher expression of MDM2 demonstrate poor DFS (P = 0.0067) and OS (P < 0.0001)